Paris & New York, September 7, 2017
Quantum Genomics (Euronext Growth − FR001164897 − ALQGC; OTCQX: QNNTF), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announced today that it will be attending the Rodman & Renshaw 19th Annual Global Investment Conference in New York, NY, being held September 10-12, 2017. Lionel Segard, Chairman and Chief Executive Officer of Quantum Genomics, will be presenting the company and meeting with investors at the conference.
Event: Rodman & Renshaw 19th Annual Global Investment Conference
Date: Tuesday, September 12, 2017
Time: 4:15pm ET
Location: Lotte New York Palace, New York, NY
If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with Quantum Genomics' management.
The presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the Investors presentations tab of the Investors section of the Quantum Genomics website at www.quantum-genomics.com.
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Euronext market in Paris (ISIN code FR0011648971, Ticker: ALQGC) and also trading in the U.S. on OTCQX (Ticker: QNNTF).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance & communication (Europe)
+33 1 53 67 36 73
Edison Advisors (U.S.)
+1 (646) 653-7035
Powered by Actusnews Wire (press release services) ©